Discontinuing statin therapy safe, beneficial for patients with terminal illness

Share this content:

the ONA take:

According to a new study published in the JAMA Internal Medicine, researchers from 15 Palliative Care Research Cooperative Group member sites have found that it is acceptable for patients with cancer, heart disease, and other life-limiting illness to discontinue statin medications or begin discussions about discontinuing statin therapy.

For the study, researchers analyzed the outcomes of 381 patients with a mean age of 74 who had between 1 month and 1 year left to live. About half of participants had cancer. Researchers divided the participants into two groups and had one group continue to take statins while the other group did not.

Results showed that the 212 participants survived beyond 60 days of study initiation. Researchers found no significant difference between mortality rates of those who continued statin therapy (20.3%) versus those who discontinued statin therapy (23.8%).

In regard to cost savings, the study showed that the surviving participants would save $716 each over the trial period. The national annual savings in 2014 would have been $529 million for generic statins.

Laboratory research reveals how statins inhibit metastasis of some cancers
It is acceptable for patients with cancer and other life-limiting illness to discontinue statin medications.

Research published today in JAMA Internal Medicine shows that it's okay for patients with cancer, heart disease and other life-limiting illnesses to stop taking statin medications, or at least begin conversations about making that choice.

READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs